Clinical Trials

Clinical Trial Detail

Return to search results.

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)

Research Study Number       7104
    
Principal Investigator       Scott Tykodi, MD
    
Phase       I

Look up trial at NIH

Research Study Description

Purpose

The primary purpose of this study is to determine if MDX-1105 is safe and tolerated when administered every 14 days to subjects with selected advanced or recurrent solid tumors.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- ECOG PS 0 to 2

- Relapsed/refractory renal cell carcinoma, NSCLC, malignant melanoma, epithelial ovarian cancer, colorectal adenocarcinoma

- Must have measurable disease

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- No history of severe hypersensitivity reactions to other monoclonal antibodies or any agent affecting T cell activation

- No prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody

- No active infection (viral, bacterial or fungal)

- No active autoimmune disease or a documented history of autoimmune disease or history of syndrome that requires systemic steroids or immunosuppressive medications.

- No active or latent infection

Other exclusion criteria may apply.



Research Study Number       7104
    
Contact       Phase 1 Program, Study Line
    
Telephone       206/288-7551
    
E-mail      
    
    

Keywords
Colon Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Gynecological Cancer; Kidney Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Renal Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.